N/A N=14 Effect of Respiratory Exerciser on Pulmonary Functions of COVID-19 Patients
Covid19 · Respiratory Function Loss · Coronavirus Infection
Primary: Change in Peak Expiratory Flow (Absolute Value) — 175; 160 ml/min — p=0.374
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=93 Increasing Physical Activity in COPD Through Rhythmically Enhanced Music
COPD Patients and Patients Recovering From COVID19
Primary: Six-minute Walk Distance — 452; 429 meters — p=0.85
Phase 2 N=18 Dual MRI for Cardiopulmonary COVID-19 Long Haulers
Covid19
Primary: Red Blood Cell to Membrane (RBC:M) Ratio — 0.39; 0.51 ratio (RBC:M)
N/A N=169 Screening for Chronic Obstructive Pulmonary Disease in Patients With Acute Coronary Syndromes
Chronic Obstructive Pulmonary Disease · Acute Coronary Syndromes
Primary: COPD Diagnosis — 39 participants
N/A N=240 Improving Patient-Centered Care Delivery Among Patients With Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
Primary: Mean Number of Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations and Emergency Department (ED) Visits Per Patient Within Each Study Arm — 0.72; 1.40…
N/A N=25 Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients
COPD · Dyspnea
Primary: Average Distance During Modified 6 Minute Walk Test — 128.0; 129.9; 137.5; 121.3 meters — p=0.02
Phase 2 N=5 Treat COVID-19 Patients With Regadenoson
COVID-19 · Lung Inflammation
Primary: Proportion of Patients Alive and Free of Respiratory Failure Through the 30-day Trial. — 100 Percentage of of patients alive and free
N/A N=5 The Impact of a Home-based Pulmonary Telerehabilitation Program in Acute Exacerbations of COPD
Pulmonary Disease, Chronic Obstructive
Primary: Quadriceps Muscle Strength Testing Change
N/A N=33 Development of a Rehabilitation Strengthening and Mobility Program for Ventilator Dependent Older Patients
Respiration, Artificial · Critical Illness · Chronic Disease
Primary: Functional Assessment: Handgrip — 3.6; 1.3 kg
N/A N=56 COPD Assessment and Management Bundle Versus Usual Care
Chronic Obstructive Pulmonary Disease
Primary: Number of Participants With Accurate Classification of Irreversible Airflow Obstruction — 10; 5 Participants
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
N/A N=209 Telehealth Pulmonary Rehabilitation for Hispanic and African-American Patients Admitted With Exacerbation of COPD
COPD Exacerbation
Primary: Composite of COPD Hospital Readmission/Death Within 6 Month of Discharge — 1.34; 1.06; 0.88; 1.35 Hospitalizations/death — p=<.05
N/A N=34 RESP-FIT: Technology-Enhanced Self-Management in COPD
COPD
Primary: Intervention Feasibility (Number of Participants Who Adhered to Treatment) — 13; 14 Participants
N/A N=192 Aides in Respiration Health Coaching for COPD
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Short Form Chronic Respiratory Disease Questionnaire (CRQ-SF) Total Score — 4.58; 4.43 units on a scale — p=.35
N/A N=252 Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study
COPD
Primary: Spirometry Measurement: Percentage of Predicted Forced Expiratory Volume in 1 Second (FEV1 %Pred) — 75.572; 100.837; 108.311; 111.849 percent of predicted FEV1 — p=<0.0001
N/A N=375 Home Pulmonary Rehabilitation for COPD
Chronic Obstructive Pulmonary Disease (COPD) · Emphysema
Primary: Change in Quality of Life — 0.37; -0.17; 0.43; -0.08 score on a scale
N/A N=4,832 An Evaluation of Post Discharge Utilization Among Patients With an Acute Exacerbation of COPD
Chronic Obstructive Pulmonary Disease
Primary: Healthcare Utilization — 1080; 920 Participants — p=0.041
N/A N=44 Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors
Covid-19 · Deconditioning
Primary: Adherence (Primary Feasibility/Safety Outcome) — 93 % of participants meeting adherence
Phase 4 N=26 Inhaler Lung Deposition in Chronic Obstructive Pulmonary Disease (COPD)
CHRONIC OBSTRUCTIVE PULMONARY DISEASE · ASTHMA · HEALTHY SUBJECTS
Primary: ANALYSIS OF LUNG DEPOSITION - Penetration Index — 0.8; 0.72; 0.69; 0.58 ratio
N/A N=153 The Effect of Physical Activity Promotion on Short and Long-term Outcomes in COPD
COPD · Emphysema · Chronic Bronchitis
Primary: 6-Minute Walk Test Distance — 25; 37 meters — p=0.189
N/A N=80 Sustainability of Pulmonary Rehab Gains
COPD
Primary: Duration of Exercise Time on a Constant Work-rate Treadmill Test — 12.2; 12.5 change in number of minutes walked — p=0.94
N/A N=200 Chronic Obstructive Pulmonary Disease Patient Preferences Survey
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants Who Prioritized Healthcare Topics — 90; 79; 23; 22 participants — p=.91
N/A N=124 Electronic Proactive Outreach for Smokers With COPD
Pulmonary Disease, Chronic Obstructive · Smoking
Primary: Participation in Tobacco Cessation Treatment — 9; 29 Participants
N/A N=292 Impact of a Peer Support Program Amongst COPD Patients and Their Caregivers
COPD
Primary: Change in Health-related Quality of Life at 6 Months — -1.78; -0.52 units on a scale — p=0.467
N/A N=146 Home-Based Health Management of COPD Patients
Chronic Obstructive Pulmonary Disease
Primary: Change in Number of Daily Steps Between the Intervention and Control Conditions — -344.8; -975.8 steps
N/A N=43 Association Between Increased Oxidative Stress, Anti-Inflammatory Fatty Acid Formation, and Airway Infection in People With Asthma and Chronic Obstructive Pulmonary Disease
Asthma · Pulmonary Disease, Chronic Obstructive
Primary: 8-isoprostane Levels as Biochemical Markers for Nonenzymatic Oxidative Stress in Asthma — 292.4; 421.8 pg/ml
N/A N=27 Doxycycline for COPD in HIV-Infected Patients
HIV · Chronic Obstructive Pulmonary Disease (COPD) · Emphysema
Primary: Safety of Doxycycline, as Measured by the Number of Subjects With Any Treatment-related Adverse Events. — 3; 1 Participants
N/A N=81 Effect of Increased Fruit and Vegetable Intake on Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease
Primary: Self-reported Intake of Fruit and Vegetables (Number of Portions Per Day); — 1.9; 6.1 Portions per day
Phase 3 N=122 GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
Pulmonary Disease, Chronic Obstructive
Primary: Number of Participants With Any Adverse Events (AEs) and Serious AEs (SAEs) — 120; 27 Participants
N/A N=15 Acute Effects of a Flutter Device in COPD
Chronic Obstructive Pulmonary Disease
Primary: Airways Resistance (IOS) — 0.63; 0.61; 0.58; 0.68 kPa/L/s — p=<0.05